biepitope BCMA CAR-T
/ Hebei Taihe Chunyu Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
July 16, 2024
Nanobody-based Biepitope CAR-T Cells Targeting BCMA in the Treatment of R/RMM
(clinicaltrials.gov)
- P1/2 | N=60 | Recruiting | Sponsor: Wuhan Union Hospital, China
New P1/2 trial • Hematological Malignancies • Multiple Myeloma • Oncology
1 to 1
Of
1
Go to page
1